Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

(2017) E. Havrdova et al.   EUROPEAN JOURNAL OF NEUROLOGY

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Treatment decisions in multiple sclerosis — insights from real-world observational studies

(2017) Maria Trojano et al.   Nature Reviews Neurology

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study

(2016) A. Miclea et al.   JOURNAL OF NEUROLOGY

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Overview of the management of relapsing−remitting multiple sclerosis and practical recommendations

(2015) P. Gallo et al.   EUROPEAN JOURNAL OF NEUROLOGY

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

(2014) J. Theodore Phillips et al.   Multiple Sclerosis and Related Disorders

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE